{"disease":{"id":"systemic-juvenile-idiopathic-arthritis-sjia","name":"systemic juvenile idiopathic arthritis sjia"},"drugs":{"marketed":[{"drug_id":"tocilizumab","indication_name":"Systemic Juvenile Idiopathic Arthritis (SJIA)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Roactemra","generic_name":"tocilizumab","company_name":"Roche","drug_phase":"marketed","molecular_target":"Interleukin-6 receptor","drug_class":"Interleukin-6 Receptor Antagonist [EPC]","quality_score":10,"revenue":null,"mechanism":"Roactemra works by blocking the interleukin-6 receptor, a protein that plays a key role in inflammation."}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT02296424","title":"ß-SPECIFIC 4 Patients: Study of Pediatric EffiCacy and Safety wIth FIrst-line Use of Canakinumab","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":182,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT06838143","title":"Ilaris NIS in Korea","phase":"","overall_status":"RECRUITING","enrollment_count":25,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT06718049","title":"Role of Interleukin 18 (IL-18) and Interleukin 18 Binding Protein (IL-18BP) in the Diagnostic Work-up of Systemic Juvenile Idiopathic Arthritis and Autoinflammatory Diseases: Possible Biomarkers in the Differential Diagnosis of Other Febrile Diseases","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":9,"lead_sponsor_name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","has_results":false}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}